Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 159,900 shares, an increase of 300.8% from the September 30th total of 39,900 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 3,050,000 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. CVI Holdings LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned 19.69% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is owned by hedge funds and other institutional investors.

Bluejay Diagnostics Stock Performance

BJDX stock opened at $0.11 on Friday. The firm has a market cap of $35,380.80, a PE ratio of 0.00 and a beta of 0.70. Bluejay Diagnostics has a one year low of $0.08 and a one year high of $34.24. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $1.83.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Wednesday, August 14th. The company reported ($5.12) earnings per share (EPS) for the quarter.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.